The PennZone

  • Home
  • Business
  • Health
  • Non-profit
  • Technology
  • Travel
  • Financial
  • Services
  • Construction

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • Pawprint Oxygen Turns Pet Safety Viral With "Pets Live Here" Window Decals — Helping First Responders Save Lives
  • New Report Reveals Surprising Trends in Illinois Airport Accidents
  • Adam Clermont Releases New Book – Profit Before People: When Corporations Knew It Was Dangerous and Sold It Anyway
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
  • CryptaBox Introduces a Hardware Crypto Cold Storage Wallet
  • YWWSDC Launches AI-Native Digital Asset Infrastructure, Merging Technical Innovation with US-Standard Compliance
  • High-End Exterior House Painting in Boulder, Colorado
  • Simpson and Reed Co-Founders Shardé Simpson, Esq. and Ciara Reed, Esq. Launch "Hello Wilma,"

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Enders Capital: 25% Gains with Just -0.80% Maximum Monthly Drawdown in Volatile Debut Year 2025
  • CES Spotlight Highlights Need for Strategic Review as Throughput Demands Evolve
  • ASR Media, Social T Marketing & PR Announce Merger
  • $780,000 Project for New Middle East Police Service with Deposit Received and Preliminary Design Work Underway for Lamperd: Stock Symbol: LLLI
  • The 3rd Annual Newark Summit for Real Estate, Economic Development & Placemaking Returns February 9th
  • Ski Safety Awareness Month highlights why seeing clearly and wearing modern protection matters more than ever
  • Vent Pros Expands Operations into Arizona to Meet Growing Demand for Commercial Ventilation and Kitchen Hood Cleaning Services
  • Klein Civil Rights Expands with New Offices in New York's Historic Woolworth Building
  • Biz Hub Financial Hosts 9th Annual Client Appreciation Event, Awards $1,000 CARES Community Grant
  • Green Office Partner Appoints Aaron Smith as Chief Revenue and Growth Officer
  • A Family Completes a Full Circumnavigation of the Globe in a Self-Contained Camper Van
  • Former Google Search Team Member Launches AI-Powered SEO Consultancy in Las Vegas
  • Q3 2025 Arizona Technology Industry Impact Report Highlights Shifting Job Demand, Semiconductor Momentum and Workforce Investment
  • $6.4 Million Purchase of Construction Vehicles Plus New Dealership Agreement with Cycle & Carriage for Heavy Equipment Provider to Singapore Region
  • CCHR Says Mounting Evidence of Persistent Sexual Dysfunction From Antidepressants Demands FDA Action
  • Acmeware and Avo Partner to Bring Real-Time Data Integration to MEDITECH Customers
  • Talented Learning Unveils 2026 "Office Hours for LMS Buyers" Webinar Series
  • New Analysis Reveals Most Patients Discontinue Weight Loss Drugs Within First Year
  • Bargeld Financial Launches Professional, Affordable Tax Preparation Services for the 2026 Tax Season
  • International Law Group Expands Emergency Immigration Consultations for Somali Minnesotans Amid ICE Actions

Popular on PennZone

  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 281
  • Neurosurgeon Chengyuan Wu, MD, MSBmE, Joins the Actuated Medical Advisory Board - 160
  • NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
  • Children Rising Appoints Marshelle A. Wilburn as New Executive Director
  • Bent Danholm Joins The American Dream TV as Central Florida Host
  • Harry Hayman of Feed Philly Coalition Proudly Supports Sharing Excess' Holiday Food Rescue — Bri
  • CredHub and Real Property Management Join Forces to Empower Franchise Owners with Rental Payment Credit Reporting Solutions
  • Top Tips for Hiring HVAC Contractors in Philadelphia
  • Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
  • Russellville Huntington Learning Center Expands Access to Literacy Support; Approved Provider Under Arkansas Department of Education

Similar on PennZone

  • SNS Research Launches SNS Market Intelligence Platform for visual market intelligence for pharma
  • High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
  • AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
  • VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us